These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 22544263

  • 21. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital.
    Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, Handa Y, Hayashi M, Koyama Y, Arii K, Kitaori T, Hagiyama H, Urushidani Y, Yamasaki T, Ikeno Y, Suzuki T, Omoto A, Sugitani T, Morita S, Inokuma S.
    Arthritis Res Ther; 2019 Nov 28; 21(1):255. PubMed ID: 31779676
    [Abstract] [Full Text] [Related]

  • 22. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections.
    Chiu YM, Lai MS, Chan KA.
    PLoS One; 2018 Nov 28; 13(4):e0196210. PubMed ID: 29694398
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.
    Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G.
    Clin Exp Rheumatol; 2013 Nov 28; 31(1):25-30. PubMed ID: 22935442
    [Abstract] [Full Text] [Related]

  • 25. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L.
    Int J Rheum Dis; 2017 Jul 28; 20(7):859-869. PubMed ID: 28160426
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
    Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D.
    Eur J Gastroenterol Hepatol; 2017 Jan 28; 29(1):56-60. PubMed ID: 27669175
    [Abstract] [Full Text] [Related]

  • 27. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy.
    Rodríguez-Tajes S, Miralpeix A, Costa J, López-Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X.
    J Viral Hepat; 2021 Jan 28; 28(1):89-94. PubMed ID: 32969557
    [Abstract] [Full Text] [Related]

  • 28. HBV reactivation in HBsAg-/HBcAb+ rheumatoid arthritis patients receiving biologic/targeted synthetic DMARDs.
    Kuo MH, Tseng CW, Ko PH, Wang ST, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS.
    Liver Int; 2024 Feb 28; 44(2):497-507. PubMed ID: 38010984
    [Abstract] [Full Text] [Related]

  • 29. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
    Wang ST, Tseng CW, Hsu CW, Tung CH, Huang KY, Lu MC, Lai NS.
    Int J Rheum Dis; 2021 Nov 28; 24(11):1362-1369. PubMed ID: 34506078
    [Abstract] [Full Text] [Related]

  • 30. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
    Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF.
    J Clin Oncol; 2014 Nov 20; 32(33):3736-43. PubMed ID: 25287829
    [Abstract] [Full Text] [Related]

  • 31. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.
    Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS.
    Dig Dis Sci; 2021 Nov 20; 66(11):4026-4034. PubMed ID: 33387124
    [Abstract] [Full Text] [Related]

  • 32. Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.
    Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R.
    Eur J Intern Med; 2014 Jun 20; 25(5):482-4. PubMed ID: 24495663
    [Abstract] [Full Text] [Related]

  • 33. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
    Elbedewy TA, Elashtokhy HE, Rabee ES, Kheder GE.
    J Egypt Natl Canc Inst; 2015 Mar 20; 27(1):11-8. PubMed ID: 25716703
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.
    Elkady A, Aboulfotuh S, Ali EM, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Iijima S, Tanaka Y.
    World J Gastroenterol; 2013 Oct 07; 19(37):6214-20. PubMed ID: 24115819
    [Abstract] [Full Text] [Related]

  • 37. The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
    Spaan M, Bruce M, Agarwal K, Carey I.
    Antivir Ther; 2018 Oct 07; 23(6):539-542. PubMed ID: 30309997
    [Abstract] [Full Text] [Related]

  • 38. Quantification of HBV core antibodies may help predict HBV reactivation in patients with lymphoma and resolved HBV infection.
    Yang HC, Tsou HH, Pei SN, Chang CS, Chen JH, Yao M, Lin SJ, Lin J, Yuan Q, Xia N, Liu TW, Chen PJ, Cheng AL, Hsu C, Taiwan Cooperative Oncology Group.
    J Hepatol; 2018 Aug 07; 69(2):286-292. PubMed ID: 29551710
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.